{"id":819625,"date":"2025-02-27T16:48:31","date_gmt":"2025-02-27T21:48:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/"},"modified":"2025-02-27T16:48:31","modified_gmt":"2025-02-27T21:48:31","slug":"myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/","title":{"rendered":"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools"},"content":{"rendered":"
\n

SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc<\/a>. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi<\/a>, a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi\u2019s risk assessment program<\/a> and access to breast specialists <\/a>with Myriad\u2019s MyRisk<\/a>\u00ae<\/sup><\/a> with RiskScore<\/a>\u00ae<\/sup><\/a> Hereditary Cancer Test<\/a>.<\/p>\n

\u201cAfter losing my mom to breast cancer and my own breast cancer diagnosis, I am passionate about eradicating late-stage breast cancer by helping women understand their risk and access the care they need,\u201d said Kaitlin Christine, Founder and CEO, Gabbi. \u201cGenetic testing is a crucial aspect of assessing a woman\u2019s risk and highly informs her care. The gold-standard MyRisk with RiskScore Hereditary Cancer Test delivers clear, actionable results, which can become the foundation for a personalized care plan.\u201d<\/p>\n

Gabbi\u2019s telehealth solution provides logistics and educational support to assess breast cancer risk. Patients identified as potentially high risk are connected with a Gabbi clinician to be evaluated for the MyRisk Hereditary Cancer Test, ensuring a seamless experience.<\/p>\n

The precision science behind MyRisk with RiskScore enables 53% of patients1<\/sup> to qualify for a medical management change\u2014 such as more frequent mammograms or MRI imaging\u20142<\/sup>\u00a0with other hereditary cancer tests.<\/p>\n

\u201cHereditary cancer risk assessment may provide peace of mind and help inform access to early detection screening tools for women at an elevated risk for cancer,\u201d said Melissa Gonzales, President, Myriad Women\u2019s Health. \u201cWe fully support Gabbi\u2019s mission to empower women to better understand their risk of breast cancer and make informed health decisions, as it aligns with our own mission as well.\u201d<\/p>\n

\n About Gabbi<\/strong>
\n
Gabbi empowers thousands of women to understand and reduce their risks of breast cancer. Gabbi\u2019s clinicians are available on the same day to answer patient questions, help them understand their risk, and develop a plan to manage and reduce cancer risks including ordering and prescribing necessary imaging and testing. Once a woman knows her risk, Gabbi \u2013 supported by its team of clinical breast specialists \u2013 equips her with a personalized action plan and real-time care navigation. This ensures the woman receives the care she needs when she needs it and gets to an early detection. For more information, visit www.gabbi.com<\/u><\/a>.<\/p>\n

\n About Myriad Genetics<\/strong>
\n
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs.\u00a0For more information, visit www.myriad.com<\/u><\/a>.<\/p>\n

\n Safe Harbor Statement<\/strong>
\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to hereditary cancer risk assessment and how it may provide peace of mind and help inform access to early detection screening tools for women at an elevated risk for cancer. These \u201cforward-looking statements\u201d are management\u2019s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company\u2019s filings with the U.S. Securities and Exchange Commission, including the company\u2019s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company\u2019s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.\u00a0<\/p>\n

\n Investor Contact<\/strong>
\n
Matt Scalo
(801) 584-3532
IR@myriad.com<\/u><\/a><\/p>\n

\n Media Contact<\/strong>
\n
Kate Schraml
(224) 875-4493
PR@myriad.com<\/u><\/a><\/p>\n

\n _________________________
1<\/sub><\/sup>
\n Myriad internal data based on MyRisk tests reported between 9\/1\/2021 and 02\/01\/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.<\/sub>
\n
\n
\n 2<\/sup>
\n
\n American Cancer Society<\/u>
\n <\/a>. \u201cBreast Cancer Risk Factors You Cannot Change.\u201d<\/sub>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi\u2019s risk assessment program and access to breast specialists with Myriad\u2019s MyRisk\u00ae with RiskScore\u00ae Hereditary Cancer Test. \u201cAfter losing my mom to breast cancer and my own breast cancer diagnosis, I am passionate about eradicating late-stage breast cancer by helping women understand their risk and access the care they need,\u201d said Kaitlin Christine, Founder and CEO, Gabbi. \u201cGenetic testing is a crucial aspect of assessing a woman\u2019s … <\/p>\n

Continue reading “Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-819625","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMyriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi\u2019s risk assessment program and access to breast specialists with Myriad\u2019s MyRisk\u00ae with RiskScore\u00ae Hereditary Cancer Test. \u201cAfter losing my mom to breast cancer and my own breast cancer diagnosis, I am passionate about eradicating late-stage breast cancer by helping women understand their risk and access the care they need,\u201d said Kaitlin Christine, Founder and CEO, Gabbi. \u201cGenetic testing is a crucial aspect of assessing a woman\u2019s … Continue reading "Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T21:48:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NjI5MSM2NzgzMTcyIzIwMDc4ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools\",\"datePublished\":\"2025-02-27T21:48:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/\"},\"wordCount\":706,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NjI5MSM2NzgzMTcyIzIwMDc4ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/\",\"name\":\"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NjI5MSM2NzgzMTcyIzIwMDc4ODc=\",\"datePublished\":\"2025-02-27T21:48:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NjI5MSM2NzgzMTcyIzIwMDc4ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NjI5MSM2NzgzMTcyIzIwMDc4ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/","og_locale":"en_US","og_type":"article","og_title":"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - Market Newsdesk","og_description":"SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi\u2019s risk assessment program and access to breast specialists with Myriad\u2019s MyRisk\u00ae with RiskScore\u00ae Hereditary Cancer Test. \u201cAfter losing my mom to breast cancer and my own breast cancer diagnosis, I am passionate about eradicating late-stage breast cancer by helping women understand their risk and access the care they need,\u201d said Kaitlin Christine, Founder and CEO, Gabbi. \u201cGenetic testing is a crucial aspect of assessing a woman\u2019s … Continue reading \"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-27T21:48:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NjI5MSM2NzgzMTcyIzIwMDc4ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools","datePublished":"2025-02-27T21:48:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/"},"wordCount":706,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NjI5MSM2NzgzMTcyIzIwMDc4ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/","name":"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NjI5MSM2NzgzMTcyIzIwMDc4ODc=","datePublished":"2025-02-27T21:48:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NjI5MSM2NzgzMTcyIzIwMDc4ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NjI5MSM2NzgzMTcyIzIwMDc4ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-assessment-tools\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=819625"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819625\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=819625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=819625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=819625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}